Rice Hall James & Associates LLC Cuts Holdings in Medpace Holdings, Inc. $MEDP

Rice Hall James & Associates LLC lowered its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.6% during the first quarter, Holdings Channel.com reports. The firm owned 53,983 shares of the company’s stock after selling 8,531 shares during the quarter. Medpace accounts for about 1.4% of Rice Hall James & Associates LLC’s portfolio, making the stock its 22nd largest position. Rice Hall James & Associates LLC’s holdings in Medpace were worth $25,922,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in MEDP. Lombard Odier Asset Management USA Corp purchased a new stake in shares of Medpace during the first quarter worth approximately $220,000. Waverly Advisors LLC raised its holdings in Medpace by 89.2% in the first quarter. Waverly Advisors LLC now owns 3,931 shares of the company’s stock valued at $1,888,000 after acquiring an additional 1,853 shares in the last quarter. Wealth Alliance LLC lifted its stake in Medpace by 8.3% in the first quarter. Wealth Alliance LLC now owns 832 shares of the company’s stock worth $400,000 after acquiring an additional 64 shares during the last quarter. Epoch Investment Partners Inc. lifted its stake in Medpace by 386.8% in the first quarter. Epoch Investment Partners Inc. now owns 140,959 shares of the company’s stock worth $67,687,000 after acquiring an additional 112,001 shares during the last quarter. Finally, Empirical Finance LLC grew its holdings in Medpace by 81.0% during the 1st quarter. Empirical Finance LLC now owns 12,663 shares of the company’s stock worth $6,081,000 after acquiring an additional 5,667 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MEDP shares. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and raised their price objective for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. TD Cowen boosted their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday. Barclays set a $600.00 target price on Medpace in a report on Thursday. Truist Financial raised their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday. Two equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Medpace presently has an average rating of “Hold” and an average price target of $560.92.

Insider Activity at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 20.50% of the stock is owned by company insiders.

Medpace Stock Down 0.7%

Shares of Medpace stock opened at $601.38 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The firm’s 50 day moving average is $492.09 and its two-hundred day moving average is $494.49. The firm has a market capitalization of $17.18 billion, a P/E ratio of 35.25, a P/E/G ratio of 2.93 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.59 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.